Results 111 to 120 of about 112,374 (313)
Hijacking the Electron Train: Menaquinone‐Binding Antimicrobial Peptides
Menaquinone is an emerging target for antimicrobial peptides. Could it be the new Achilles’ Heel of bacteria? The rise of antibiotic resistance threatens to undermine modern medicine, making the development of new antibiotics and novel targets an urgent priority.
Eilidh J. Matheson, Stephen A. Cochrane
wiley +1 more source
Balloon Aortic Valvuloplasty Prior to Self‐Expanding TAVI: The BAVSE‐TAVI Registry
ABSTRACT Background Direct transcatheter aortic valve implantation (TAVI) approach is feasible and safe compared to predilatation‐TAVI. Certain clinical and computerized tomography (CT)‐based characteristics might indicate the need for balloon aortic valvuloplasty (BAV) before TAVI, especially with self‐expanding valves.
Abdalazeem Ibrahem+9 more
wiley +1 more source
AimsThis study aimed to identify predictors of heart failure (HF) rehospitalization and explore their association with mortality in patients with preserved (HFpEF), and mildly reduced (HFmrEF) ejection fraction, leading to the development of a ...
Flavia-Mihaela Stoiculescu+13 more
doaj +1 more source
ABSTRACT Vasoplegic syndrome (VS) is a common complication after cardiac surgery with cardiopulmonary bypass (CPB). The main pathophysiology mechanism of VS includes a systemic inflammatory response syndrome due to surgical trauma, release of pro‐inflammatory mediators caused by blood contact with foreign surfaces of heart‐lung machine (pump and tubing)
Matteo Lucchelli+3 more
wiley +1 more source
Editorial: Edema in heart failure with reduced ejection fraction
Inna P. Gladysheva+2 more
openaire +3 more sources
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established.
Scott D. Solomon+58 more
openaire +5 more sources
ABSTRACT Background Comorbidities like a history of chronic obstructive pulmonary disease (COPD), atrial fibrillation (AF) and heart failure (HF) can cause similar symptoms as aortic stenosis (AS). However, how they influence symptom improvement and long‐term outcomes after transcatheter aortic valve implantation (TAVI) is unclear.
Kees H. van Bergeijk+21 more
wiley +1 more source
ABSTRACT Background Valve‐in‐valve (ViV) procedures are an established therapy. Self‐expanding (SE) supra‐annular transcatheter heart valves (THV) achieve superior hemodynamics compared to balloon‐expandable (BE) intra‐annular THV, but influence of stent design versus valve position remains unclear.
Antonia Katharina Stötzel+9 more
wiley +1 more source
ABSTRACT Background Despite the emergence of the transcaval (TCv) access route for transcatheter aortic valve implantation (TAVI) in the treatment of patients with hostile iliofemoral anatomy, the number of patients reported in clinical series of TCv TAVI has been relatively small (< 500 published cases). We assessed procedural and clinical outcomes in
Conor J. Doyle+6 more
wiley +1 more source